AU2005221195B2 - Modified annexin proteins and methods for preventing thrombosis - Google Patents

Modified annexin proteins and methods for preventing thrombosis Download PDF

Info

Publication number
AU2005221195B2
AU2005221195B2 AU2005221195A AU2005221195A AU2005221195B2 AU 2005221195 B2 AU2005221195 B2 AU 2005221195B2 AU 2005221195 A AU2005221195 A AU 2005221195A AU 2005221195 A AU2005221195 A AU 2005221195A AU 2005221195 B2 AU2005221195 B2 AU 2005221195B2
Authority
AU
Australia
Prior art keywords
seq
annexin
protein
linker
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005221195A
Other languages
English (en)
Other versions
AU2005221195A1 (en
Inventor
Anthony Allison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alavita Pharmaceuticals Inc
Original Assignee
Alavita Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alavita Pharmaceuticals Inc filed Critical Alavita Pharmaceuticals Inc
Publication of AU2005221195A1 publication Critical patent/AU2005221195A1/en
Application granted granted Critical
Publication of AU2005221195B2 publication Critical patent/AU2005221195B2/en
Assigned to ALAVITA PHARMACEUTICALS, INC. reassignment ALAVITA PHARMACEUTICALS, INC. Request for Assignment Assignors: ALAVITA, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2005221195A 2004-03-11 2005-03-10 Modified annexin proteins and methods for preventing thrombosis Ceased AU2005221195B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US55242804P 2004-03-11 2004-03-11
US60/552,428 2004-03-11
US57958904P 2004-06-14 2004-06-14
US60/579,589 2004-06-14
PCT/US2005/008193 WO2005086955A2 (en) 2004-03-11 2005-03-10 Modified annexin proteins and methods for preventing thrombosis

Publications (2)

Publication Number Publication Date
AU2005221195A1 AU2005221195A1 (en) 2005-09-22
AU2005221195B2 true AU2005221195B2 (en) 2011-05-19

Family

ID=34976262

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005221195A Ceased AU2005221195B2 (en) 2004-03-11 2005-03-10 Modified annexin proteins and methods for preventing thrombosis

Country Status (5)

Country Link
EP (1) EP1734983A4 (enExample)
JP (2) JP5134362B2 (enExample)
AU (1) AU2005221195B2 (enExample)
CA (1) CA2559167A1 (enExample)
WO (1) WO2005086955A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635676B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
EP2328622B1 (en) 2008-08-26 2014-12-17 MosaMedix B.V. Radiolabelled annexins
WO2013022328A1 (en) * 2011-08-09 2013-02-14 Uab Profarma Derivatives of recombinant proteins, homo-multimers of granulocyte colony-stimulating factor and method of preparation thereof
GB2542391A (en) * 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
US11357823B2 (en) * 2019-08-30 2022-06-14 Suzhou Yabao Pharmaceutical R&D Co., Ltd Method for treating cerebral stroke
TW202146042A (zh) * 2020-03-06 2021-12-16 瑞典商阿斯特捷利康公司 用於治療動脈和靜脈血栓形成的協同且靶向的組成物
CN117897399A (zh) * 2021-06-14 2024-04-16 Inserm(法国国家健康医学研究院) 突变的膜联蛋白a5多肽及其在治疗目的中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002587A1 (en) * 1998-07-13 2000-01-20 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
CN1247195A (zh) * 1999-03-12 2000-03-15 中国科学院上海生物化学研究所 一种血栓靶向性溶栓融合蛋白
US6171577B1 (en) * 1994-01-24 2001-01-09 Neorx Corporation Radiolabeled annexins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3742675B2 (ja) * 1995-06-28 2006-02-08 東菱薬品工業株式会社 虚血−再灌流障害の予防および治療薬
EP1839670A3 (en) * 2001-02-21 2009-11-11 Alavita Pharmaceuticals, Inc. Modified Annexin Proteins and their use against thrombosis
US20030152513A1 (en) * 2001-09-06 2003-08-14 Imetrix, Inc. Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector
WO2003103577A2 (en) * 2002-06-06 2003-12-18 Tze Chein Wun Novel recombinant anticoagulant proteins
WO2004013303A2 (en) * 2002-08-02 2004-02-12 Surromed, Inc. Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171577B1 (en) * 1994-01-24 2001-01-09 Neorx Corporation Radiolabeled annexins
WO2000002587A1 (en) * 1998-07-13 2000-01-20 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6312694B1 (en) * 1998-07-13 2001-11-06 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
CN1247195A (zh) * 1999-03-12 2000-03-15 中国科学院上海生物化学研究所 一种血栓靶向性溶栓融合蛋白

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
http://search.cnpat.com.cn/Search/EN/) *
SUN et al., 'Interaction of Annexin V and Platelets: Effects on Platelet Function and Protein S Binding' Thrombosis Research. 1993, Vol. 69, pages 289-296. *
TAIT et al., 'Prourokinase-Annexin V Chimera' Journal of Biological Chemistry' 15 September 1995, Vol. 270, No. 27, pages 21594-21599 *
THIAGARAJAN et al., 'Inhibition of Arterial Thrombosis by Recombinant Annexin V in Rabbit Carotid Artery Injury Model' Circulation. 7 October 1997, Vol. 96, NO. 7, pages *

Also Published As

Publication number Publication date
WO2005086955A2 (en) 2005-09-22
CA2559167A1 (en) 2005-09-22
AU2005221195A1 (en) 2005-09-22
EP1734983A2 (en) 2006-12-27
JP2008502592A (ja) 2008-01-31
EP1734983A4 (en) 2009-11-18
JP2012254992A (ja) 2012-12-27
JP5134362B2 (ja) 2013-01-30
WO2005086955A3 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
US20050222030A1 (en) Modified annexin proteins and methods for preventing thrombosis
US7407475B2 (en) Modified annexin proteins, and methods and compositions for using them
US7635680B2 (en) Attenuation of reperfusion injury
WO2008008982A2 (en) Modified annexin proteins and methods for their use in platelet storage and transfusion
US7635678B2 (en) Modified annexin compositions and methods of using same
JP2012254992A (ja) 修飾アネキシンタンパク質および血栓症を防止するための方法
US20090291086A1 (en) Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
KR20200116098A (ko) 항응고제 단백질 및 호중구의 활성화와 관련된 질환을 치료하기 위한 이의 용도
WO2004013303A2 (en) Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease
JP4873784B2 (ja) 膜結合能を有する可溶性ペプチド化合物の複合体を含有する器官移植用溶液
US6982154B2 (en) Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ALAVITA PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): ALAVITA, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired